Efficacy of Quetiapine in Generalised Social Anxiety Disorder

• Status: Terminated
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with the LSAS

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Written Confirmed Consent,

• All patients meet the DSM IV criteria for generalized social anxiety disorder,

• A score ≥ 60 on the LSAS,

• male and female aged between 18 and 65 years

Exclusion Criteria:

• Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV,

• alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months,

• any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder,

• patients at risk of suicide